Introduction
The last decade has seen many studies on hyperhomocysteinemia (HHcy) in epileptic patients treated with antiepileptic drugs (AEDs). It has been shown that HHcy occurs in 10-40% of the epileptic population, 1, 2 and that AEDs pharmacotherapy has a fundamental effect on the levels of homocysteine (Hcy) in both children [3] [4] [5] and adults. [6] [7] [8] [9] Furthermore, it has been demonstrated that a specific predisposition to generate circulating Hcy in patients with gene polymorphisms in both the cystathionine beta-synthase (CBS) and methylenetetrahydrofolate reductase (MTHFR) C677T 2,7 and A1298C 10, 11 genes is an important factor in the levels of HHcy in epileptics treated with AEDs. The study by Mudd et al. 12 shows that 20% of the heterozygote CBS patients have epileptic seizures when circulating Hcy increases from 50 to 200 mM. It has also been shown that, in women with generalized idiopathic epilepsy, the frequency of the MTHFR TT (C677T) homozygote is increased, with this polymorphism also possibly increasing the risk of becoming an epileptic. 13 Moreover, it has been demonstrated that both heterozygote and homozygote individuals with the MTHFR (C677T) polymorphism have a significantly increased level of Hcy and decreased levels of folates (FA), especially in polytherapy with AEDs. 7, 14, 15 The literature indicates that Hcy formation in epileptics treated with AEDs may also involve 5,10-methylenetetrahydrofolate reductase (MTR). Studies on animal models have shown that phenytoin administration can both decrease 16 and increase 17 MTR activity.
It is also known that the three-functional enzyme, methylenetetrahydrofolate dehydrogenase/methynyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetaze (MTHFD1) is involved in the regulation of circulating Hcy. It has been shown that MTHFD1 homozygotes experience an increase in Hcy levels in heart disease and dysgenesis of the neural tube dependent on FA levels, 18 while MTHFD1 GA (G1958A) heterozygotes with Alzhei-mer's or Parkinson's disease have variable cysteine (Cys) to Hcy ratios (Cys:Hcy). 19 However, there is no literature on the contribution of MTHFD1 in the generation of Hcy in epileptics treated with AEDs. It is believed that an increased concentration of Hcy by inhibition of dimethylaminohydrolase (DDAH) may lead to an accumulation of asymmetric dimethylarginine (AMDA) and a drop in production of nitric oxide (NO). 20 Most studies looking at patients with vascular disease confirm an increase in ADMA in HHcy, [21] [22] [23] [24] but there are also indications of a disturbed relationship between Hcy and ADMA in HHcy. 25, 26 However, there is a lack of information on the effect of AEDs on ADMA in HHcy in epileptic patients. It has been shown that ADMA may also participate in the atherosclerotic function of Hcy, 22 and that an increased concentration of plasma ADMA in patients with atherosclerosis is associated with the degree of vascular endothelium dysfunction and the severity of atherosclerosis. 27, 28 The purpose of this study was to determine the frequency of polymorphism incidence for the MTHFR (C677T), MTR (A2756G), and MTHFD1 (G1958A) genes, and to analyze the levels of the sulphur-containing amino acids Hcy and Met as well as ADMA and Arg in epileptic patients treated with variable AEDs, and control group. The genotypes of the genes involved in the formation of Met from Hcy were also taken into account with regards to the analyzed biochemical parameters in the study participants.
Methods

Patients
The studies were conducted on 65 patients with epilepsy, treated with variable AEDs (Table 1 ).
In the group of patients treated with AEDs, the mean levels of VPA and CBZ were within the reference values and averaged 56.5 mg/ml and 5.8 mg/ml, respectively.
The classification of epilepsy and/or epileptic syndrome suffered by each patient was verified according to the criteria and terminology recommended by the Commission on Classification and Terminology of The International League Against Epilepsy. 29 The control group included 61 individuals, 41 women and 20 men, aged 22-67 years (mean age: 44.3 AE 14.2 years).
None of the epileptic patients and control subjects (epileptic patients and controls -Caucasian), were diagnosed with impaired liver or kidney function or smoking and drinking habits. None of the patients and controls had been receiving B group vitamin or FA supplementation. Moreover, epileptic patients, a few hours before testing took their AEDs dose.
None of the control subjects had verifiable symptoms of dementia or any other neurological disorders.
A Local Ethical Committee approved the study and the written consent of all patients or their caregivers was obtained.
Analysis of Hcy and Met concentrations 2.2.1. Preparation of samples
The analyzed plasma thiol compounds (Hcy, Fluka Germany; Met, Sigma, USA) were diluted with water at a 2:1 ratio and reduced using 1% TCEP (Tris-(2-carboxyethyl)-phosphin-hydrochloride; Applichem, Germany) at a 1:9 ratio. Subsequently, the sample was deproteinized using 1 M HClO 4 (at a 2:1 ratio) and applied to the HPLC/EC system.
Determination of thiol concentration
The samples were fed to the HPLC system (P580A; Dionex, Germany) coupled to an electrochemical detector (CoulArray 5600; ESA, USA). The analysis was performed in Termo Hypersil BDS C18 column (250 mm Â 4.6 mm Â 5 mm) (Germany) in isocratic conditions, using the mobile phase of 0.15 M phosphate buffer, pH 2.9, supplemented with 12.5-17% acetonitrile for estimation of Hcy and Met and 0.15 M phosphate buffer. 30 The system was controlled and the data were collected and processed using Chromeleon software (Dionex, Germany).
Estimation of ADMA and Arg levels
Preparation of samples and derivatization
Plasma and the standard, containing a solution of Arg and ADMA (Sigma, USA), were diluted with water at a ratio of 1.5:1.0 and, were then deproteinized using 8 M HCLO 4 at a ratio of 5:1. Directly before HPLC analysis, the samples were subjected to derivatization in a solution containing 10 mg OPA per 100 ml methanol supplemented with 900 ml 0.4 M borate buffer (pH 8.5) and 5 ml 2-mercaptoethanol at a ratio of 1:1. 
Analysis of ADMA
The samples were fed to the HPLC system (P580A; Dionex, Germany) coupled to a fluorescence detector (RF2000; Dionex, Germany). The analysis was performed in a Termo Hypersil BDS C18 column (250 mm Â 4.6 mm Â 5 mm) (Germany) in isocratic conditions using 0.1 M phosphate buffer, pH 6.75, with 25% methanol as the mobile phase. Arg and its methylated metabolites were measured fluorometrically at excitation and emission wavelengths of 340 nm and 455 nm, respectively.
The system was controlled and the data were collected and processed using Chromeleon software (Dionex, Germany).
Genotyping by RFLP
Genotyping for polymorphisms in MTHFR (C677T), MTR (A2756G) and MTHFD1 (G1958A) was conducted using PCR-RFLP technique. PCR products were generated by using 10 ng of genomic DNA in 25 ml of the reaction mixture containing 20 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl 2 , 0.11 mM each dNTP, 0.3 mM of each primer (Table 2 ) and 1 U Taq DNA polymerase (Sigma-Aldrich, USA). The PCR products were digested with an appropriate restriction endonuclease (Fermentas, Vilnius, Lithuania), which recognizes and cuts either wild-type or variant sequence, at 37 8C for at least 3 h. The digested fragments were resolved on a 2% agarose gel, in 0.5 Â TBE buffer, and were stained with ethidium bromide for visualization under UV light. The results were confirmed by direct sequencing of the amplified fragments.
Statistical analysis of results
The obtained results were analyzed using the nonparametric Mann-Whitney's test and nonparametric Kruskal-Wallis test. 
Results
The frequency of the MTHFR (C677T), MTR (A2756G) and MTHFD1 (G1958A) gene polymorphisms was studied, as were the levels of plasma Hcy and Met as well as ADMA and Arg of epileptic patients treated by variable AEDs, and the control group.
The study revealed that the epileptics treated with various AEDs have a significant increased in their plasma concentration of Hcy (Mann-Whitney test, p < 0.05 compared to controls) ( Table 3) . It was also shown that an increase in Hcy concentration above the minimum required to diagnose mild HHcy (above 16 mM) The frequency of the C677T polymorphism of the coding gene MTHFR (Table 4) was also analyzed, and demonstrated a variable distribution of genotypes of this gene both in controls and in Table 2 Primers and restriction enzymes used for genotyping various polymorphisms in patients with epilepsy and the control group. Results are presented as mean AE SD. Non-parametric Mann-Whitney test for independent variables was used. * Statistically significant difference at p < 0.05 compared to controls. ** Statistically significant difference at p < 0.01 compared to controls. *** Statistically significant difference at p < 0.001 compared to controls. (25) n: Number of subjects.
epileptic patients. The lowest number of individuals expressing the homozygous incorrect TT genotype (C677T MTHFR) was found in the control group. The epileptic patient group demonstrated a higher number of individuals homozygous for both the wildtype CC genotype and the incorrect TT genotype (nearly 3-fold increase from the control group in the case of the TT genotype) of the C677T MTHFR polymorphism. In the case of the MTR (A2756G) coding gene (Table 4) , the control group demonstrated the highest number of the wildtype AA (A2756G MTR) genotype and no homozygotes for the incorrect GG genotype (A2756G MTR). However, the patient group contained an increasing number of AG heterozygotes (A2756G MTR) and also had homozygotes for the incorrect GG genotype (A2756G MTR).
For the G1958A MTHFD1 polymorphism, the patient group contained more AA homozygotes (G1958A MTHFD1) than the control group (Table 4) , though both the control group and patient group showed the same percent of the heterozygous GA (G1958A MTHFD1) genotype. The wildtype homozygous GG genotype (G1958A MTHFD1) was observed in similar numbers in both groups, and was higher than the number of the incorrect AA genotype (G1958A MTHFD1) only in the control group.
The concentrations of the studied biochemical parameters (Hcy, Met, ADMA and Arg) were also analyzed with respect to the MTHFR (C677T) gene genotypes (Table 5 ). There was a significant increase in the concentration of Hcy (Mann-Whitney test, p < 0.05 compared to controls) and ADMA (Mann-Whitney test, p < 0.01 compared to controls) in patients treated with AEDs and having the heterozygous MTHFR CT (C677T) genotype. In patients with the wildtype homozygous MTHFR CC (C677T) genotype (MannWhitney test, p < 0.05 compared to controls), and MTHFR CT (C677T) genotype (Mann-Whitney test, p < 0.01 compared to controls) there was a significant decrease in Met concentration. Both the patients with the wildtype homozygous, MTHFR CC (C677T) (Mann-Whitney test, p < 0.05 compared to controls), and with the heterozygous MTHFR CT (C677T) genotype (MannWhitney test, p < 0.01 compared to controls), there was a decrease in both the Met:Hcy ratio and the Arg:ADMA ratio (Mann-Whitney test, in patients with MTHFR CT (C677T), p < 0.001 compared to controls). Due to the small number of individuals having the Results are presented as mean AE SD, n: number of subjects. Non-parametric Mann-Whitney test for independent variables was used. * Statistically significant difference at p < 0.05 compared to controls. ** Statistically significant difference at p < 0.01 compared to controls. *** Statistically significant difference at p < 0.001 compared to controls. Results are presented as mean AE SD, n: number of subjects. Non-parametric Mann-Whitney test for independent variables was used. * Statistically significant difference at p < 0.05 compared to controls. ** Statistically significant difference at p < 0.01 compared to controls.
homozygous MTHFR TT (C677T) genotype (2 from the control group, 7 from the patient group), this genotype was not subjected to statistical analysis of the studied biochemical parameters. In the case of epileptic patients treated with AEDs with either the wildtype homozygous MTR AA (A2756G) genotype or the MTR AG (A2756G) heterozygous genotype (Table 6) , there was no significant increase in Hcy, although these patients demonstrated a significant increased in ADMA concentration (Mann-Whitney test, p < 0.05 compared to controls). Furthermore, both in patients with the MTR AA (A2756G) wildtype homozygous genotype (MannWhitney test, p < 0.01 compared to controls) and the MTR AG (A2756G) heterozygous genotype (Mann-Whitney test, p < 0.05 compared to controls), there was a decrease in Met concentration and the Met:Hcy ratio, while in patients with just the MTR AG (A2756G) heterozygous genotype there was also a decrease in Arg concentration.
Moreover, only patients with the wildtype MTHFD1 GG (G1958A) homozygous genotype (Table 7) and treated with AEDs demonstrated a significant increase in Hcy concentration (MannWhitney test, p < 0.05 compared to controls) along with an increase in ADMA concentration (Mann-Whitney test, p < 0.001 compared to controls). The concentration of Met was decreased in both the patients with the MTHFD1 GG (G1958A) wildtype homozygous genotype (Mann-Whitney test, p < 0.05 compared to controls) and in those with the MTHFD1 GA (G1958) heterozygous genotype (Mann-Whitney test, p < 0.01 compared to controls), though the Met:Hcy ratio (Mann-Whitney test, p < 0.01 compared to controls) and Arg:ADMA radio (MannWhitney test, p < 0.001 compared to controls) was concurrently significantly decreased only in patients with the wildtype homozygous genotype, MTHFD1 GG (G1958A). There was a significant decrease in the Arg:ADMA ratio (Mann-Whitney test, p < 0.05 compared to controls) in the patients with the incorrect MTHFD1 AA (G1958A) homozygous genotype, while the patients with the MTHFD1 GA (G1958A) heterozygous genotype demonstrated a significant decrease in Arg concentration (MannWhitney test, p < 0.05 compared to controls).
It was also shown that all of the examined epileptic patients with gene polymorphisms of those genes related to Hcy-to-Met metabolism, MTHFR (C677T), MTR (A2756G), and MTHFD1 (G1958A), who had increased plasma concentrations of Hcy (whether significant and/or insignificant) had an accompanying increase in plasma concentration of ADMA (Tables 5-7 ).
Discussion
There is much published literature demonstrating an increase in the plasma concentration of Hcy in epileptic patients treated with AEDs. These articles indicate that pharmacologic treatment in epileptic patients can lead to an increase in Hcy that may be due to various factors, including the pharmacotherapy and genetic factors.
Furthermore, it appears that generation of Hcy in epileptic patients is affected mainly not by the disease itself, but the pharmacologic treatment for the disease. This is demonstrated by studies conducted on a Greek population, in epileptic children aged 4.5-14 years treated by AEDs for 20 weeks, 5 by studies conducted on epileptic adult patients treated with AEDs in mono-and polytherapy for over 30 days. 6 The generation of Hcy in epileptic patients, as demonstrated by the literature, is related both to AEDs [such as phenytoin, phenobarbital, primidone, and carbamazepine (CBZ)] inducing microsomal liver enzymes and increasing cytochrome P450 enzyme activity, which leads to a decrease in FA serum concentration, as well as AEDs [such as valproic acid (VPA)] that induce liver enzymes to a smaller degree and have a lesser effect on the concentration of FA in blood serum. 32 An increase in Hcy and accompanying decrease in FA concentration in epileptic patients after receiving CBZ was demonstrated in the studies by Verrotti et al., 3 Karabiber et al. 4 and Attilakos et al. 5 In epileptics taking VPA, an increase in Hcy concentration was demonstrated both accompanying a decrease in FA 3, 4 and without FA changes. 5 It is believed that a decrease in FA concentration during AEDs treatment is due to impaired intestinal absorption of FA, an Results are presented as mean AE SD, n: number of subjects. Non-parametric Mann-Whitney test for independent variables was used. * Statistically significant difference at p < 0.05 compared to controls. ** Statistically significant difference at p < 0.01 compared to controls. *** Statistically significant difference at p < 0.001 compared to controls.
increase in FA required for AEDs hydroxylation, the activation of liver enzymes leading to a final decrease in FA concentration, direct interactions between FA and AEDs caused by structural similarities between coenzymes for FA and AEDs, or a direct effect AEDs on Hcy metabolism and kidney function. 33 It is also known that insufficiency of the cofactors needed for the remethylation of Hcy (vitamin B12, FA) can lead to decreased efficiency of this process, which results in a decrease of Met concentration. A decrease in Met concentration in epileptic patients was demonstrated by Ono et al. 34 as well as the present study. This study has also shown that a decrease in the Met:Hcy ratio accompanied the decrease of Met concentration. According to one of the newer theories, 35 a decrease in the Met:Hcy ratio may be related to the transformation of Hcy to thiolactone in endothelium and mediate Hcy-induced atherosclerotic changes.
Engbersen et al. 36 demonstrated that there is a strong indirect effect of the MTHFR enzyme on the effectiveness of Hcy remethylation to Met. The point mutation C677T of the MTHFR encoding gene is related to the above process. According to the literature and present study, the Polish ( 19 and present study), Norwegian, 7 British, 13 Korean, 14 and Turkish 37 populations have demonstrated that the least common genotype of this gene was the homozygous genotype MTHFR TT (C677T) and appeared to have an increased frequency of occurrence in patients suffering from epilepsy. It is believed that the MTHFR encoding gene polymorphism leads to disturbances in the remethylation process of Hcy to Met and an increase in Hcy due to a decrease in FAdependent enzyme activity. It is also believed that the C ! T transition in the MTHFR (C677T) gene decreases enzyme activity by 50%, 38 while homozygous TT forms of this gene decrease its activity by 30%. 39 There are also reports in the literature that the Korean population 14 only the homozygous MTHFR TT (C677T) genotype leads to a significant increase of Hcy, and only in epileptic patients treated with medications inducing liver enzymes and decreasing FA (CBZ). In the present study, the concentration of Hcy has significantly increased in heterozygous MTHFR CT (C677T) epileptic patients treated with various AEDs both in mono-and polytherapy. Analysis of the data gives an absolute correlation of AEDs with the MTHFR C677T polymorphism. The synergistic effects of AEDs inducing liver enzymes with the heterozygous MTHFR CT (C677T) genotype are confirmed by Apeland et al. 7 Though the study by Vurucu et al. 37 demonstrates that the MTHFR C677T polymorphism is not involved in HHcy in epileptic patients treated with CBZ, while Ono et al. 15 showed that this polymorphism is only involved in HHcy in epileptic patients treated with polytherapy. It has also been shown that the use of phenytoin may lead to decreased MTR activity in the remethylation of Hcy to Met, which affects the regulation of Met levels. 16 It seems that in the present study neither mono-nor polytherapy of epileptic patients with various AEDs leads to a significant decrease in MTR enzyme activity. Furthermore, the present study demonstrates that MTHFD1 (G1958A), and especially the correct homozygous MTHFD1 GG (G1958A) genotype, is also involved in the formation of plasma Hcy in epileptic patients treated with AEDs in mono-and/or polytherapy.
The present study also shows that gene polymorphisms of the studied genes involved in remethylation of Hcy to Met in epileptic patients treated with AEDs may also contribute to disturbances in the corresponding levels of Met and Hcy, which can therefore lead to an increase in Hcy levels.
As demonstrated, an increase of Hcy concentration above 15 mM in epileptic patients treated with AEDs may lead to several clinical complications. It is known that such increases can raise the risk of myocardial infarction three-fold and the risk of carotid artery stenosis two-fold, 40 and can also lead to vascular 41, 42 and neuropsychiatric 33 diseases, as well as increasing the risk of epileptic seizures and AEDs resistance. 43 Over the past few years, there have been several articles emphasizing the correlation between HHcy and the concentration of ADMA in vascular disease. [22] [23] [24] 44 Many of these articles indicate an increase in serum ADMA in HHcy with coronary artery disease, 45 peripheral artery disease, 46 and stroke. 22 An increase in ADMA concentration in HHcy has been explained by several theories. One of these theorizes that formation of serum ADMA may occur in an environment of increased Met concentration, due to high Hcy levels in HHcy, with the participation of SAM, which leads to an increased production of ADMA from Arg via increased enzyme activity of SAM-dependent protein N-methyltransferase (PRMT) or inappropriate regulation of this gene's expression under HHcy conditions. 20, 47 Another theory suggests an increase of ADMA in HHcy resulting from decreased renal secretory function 25 or decreased expression and activity of DDAH, which is known to be responsible for breaking down ADMA to L-citrulline. 48 It has been shown that, under in vitro conditions, Hcy may directly arrest DDAH enzyme activity through its oxidative inactivation, thereby leading to an increase in ADMA concentration. 20 Increases in ADMA concentration under conditions of increasing Hcy seem to be both due to organic factors 45, 46 and due to pharmacotherapy, as shown in the present study. The present study demonstrates an increase in Hcy accompanied by an increase in ADMA in epileptic patients receiving AEDs, regardless of the medications used or the gene polymorphisms of genes encoding enzymes involved in the metabolism of Hcy to Met. Furthermore, in the studies of Jonasson et al. 25 and Wanby et al., 26 during longterm treatment with AEDs it was demonstrated that patients with vascular disease, in HHcy, the concentration of ADMA was not always increased. As has been demonstrated in vascular disease patients, a lack of ADMA increase under HHcy conditions is most likely due to a concurrent mild renal insufficiency in these patients (the secretory function of the kidneys is slightly but insignificantly increased). Furthermore, it has been shown that ADMA may participate in the atherosclerotic function of Hcy. 22 ADMA is one of the risk factors of circulatory system diseases, 49 as well as a marker of atherosclerosis. 27, 28, 50, 51 The pathological function of ADMA is related both to increase in its level and to decreased concentrations of its metabolite and substrate to NO production, Arg. The present study indicates that a decrease in Arg levels in epileptic patients may be due to certain genetic predispositions. Among the patient group, MTR AG (A2756G) and MTHFD1 GA (G1958A) heterozygotes appeared to be more predisposed to decreases in the levels of this amino acid. It also seems that a decrease in Arg levels in epileptic patients treated with AEDs may be related to the epileptogenetic mechanism, in which there is a many-fold increase in Arg-utilizing biosynthesis of neurotransmitters that have stimulatory (glutamate) and inhibitory (GABA) actions, 52, 53 or may be due to a mobilization of the organism to counteract the overstimulation caused by the action of many AEDs (increase in GABA concentration). A decrease in Arg in epileptic patients also seems to have an effect on the Arg:ADMA ratio, which according to Dayal and Lentz 54 may be due to increasing oxidative stress accompanying increases in Hcy levels. The study by Maas 55 indicates that, in conditions of oxidative stress related to pharmacologic intervention, there is ADMA generation through a change in the expression of genes responsible for the synthesis and breakdown of ADMA. The studies by Matsuoka et al. 56 and Kielstein et al. 49 demonstrate that disturbances in the Arg:ADMA ratio may lead to hypercholesterolemia, arterial hypertension, and diseases of the heart and blood vessels. Many studies have demonstrated the success of Bgroup vitamins and FA supplementation in decreasing Hcy levels in epileptic patients treated with AEDs. 46 and Koga et al. 57 indicate that, to regulate both Hcy and ADMA, patients require combined therapy with B-group vitamins, FA, and Arg. The effectiveness of this combined therapy on epileptic patients treated with AEDs appears to also be indicated by the result analysis obtained for Met and Arg after treatment with this therapy in the present study.
Conclusions
The present study demonstrates that AEDs pharmacotherapy in epileptic patients leads to increases in Hcy and ADMA levels. Individuals with the MTHFR CT (C677T) and MTHFD1 GG (G1958A) genotypes seem to have greater predisposition to Hcy concentration increase during AEDs treatment. Genetic factors also appear to be related to disturbances in Met:Hcy and Arg:ADMA ratios. Under HHcy conditions related to AEDs treatment of epileptic patients, the feedback control of Hcy over ADMA appears to be disturbed. It is possible, that polymorphisms of genes related to Hcy-to-Met metabolism, may have an effect on the regulation of levels of Hcy and ADMA in epileptics treated with AEDs.
Our results indicate that further analysis should be performed in epileptic patients treated with AEDs to determine the concentration of Hcy and ADMA, as well as genotype analysis of genes coding enzymes converting Hcy, especially MTHFR and MTHFD1, in epileptic patients with HHcy. The administration of L-arginine along with vitamins B6, B12, and folates in epileptic patients may offer new therapy in the treatment of epilepsy.
